Acute megakaryoblastic leukemia (AMKL) occurred in 89 of 1255 (7.1%) of children and adolescents below 18 years of age without Down's syndrome enrolled in the population-based studies AML-BFM 87, 93 and 98. The median age at diagnosis in these 46 male and 43 female subjects with AMKL was 1.5 years (0.3-16.7 years), which was significantly lower than in the total group of children with AML treated between 1/1987 and 12/ 1999 (n ¼ 1255; median age 8.2 years, Po0.001).
Typical features at diagnosis were hepatosplenomegaly (66%), anaemia (93%), low platelet counts (88%) and myelofibrosis. In 97% (n ¼ 86) of all children the expression of at least one megakaryoblastic antigen (CD41/CD42b or 61) could be shown. In three patients with myelofibrosis the diagnosis was confirmed by detection of CD61 in immunohistology.
Cytogenetic results (available in 67 of 89 ¼ 75% patients) showed t(1;22)(p13;q13) being the most frequent structural aberration, which was detected in 10 patients (17%) either as sole abnormality or together with various numerical and structural changes. This translocation was closely associated with a low age (median 0.35 years). Other recurrent aberrations were mainly numerical changes including trisomies of the chromosomes 19 (n ¼ 12), 21 (n ¼ 11) and 8 (n ¼ 9). Losses of seven or parts of the long arm (À7/7q-) were detected in eight children (14%). Only þ 21 (n ¼ 4) or À7 (n ¼ 1) were found as sole aberration, whereas all others were combined with structural or numerical changes. Complex karyotypes with three or more independent abnormalities could be seen in 19 children. Aberrations of 11q23 (n ¼ 4) also found in three patients with t(9;11), additional der(3q) (n ¼ 2), and À5/5q-(n ¼ 1) were rare.
All children with AMKL were classified as high-risk (HR) AML patients according to the previously published criteria. 1 As reported, the treatment schedules of the AML-BFM trials 87, 93 and 98 consisted of induction, consolidation, intensification, prophylactic CNS irradiation and maintenance treatment. The most relevant difference between the AML-BFM 87 and the AML-BFM 93/98 studies was the introduction of HAM (highdose cytarabine (12 Â 3 g) and mitoxantrone (2 Â 10 mg)). 2 For patients with an HLA compatible sibling donor allogeneic stem cell transplantation (alloSCT) in 1st complete remission (CR) was indicated. Thirteen of the 67 children who achieved 1st CR were transplanted, nine according to recommendation from a matched sibling donor (MSD), another four from a matched unrelated donor (MUD).
Regarding the total group, the CR rate (75%) was comparable to other children with HR-AML. However, there was a significant improvement in the CR rate in AMKL patients from study AML-BFM 87 (58%) to AML-BFM 93 (77%) and AML-BFM 98 (84%) >ðP w 2 o0:05Þ. The percentage of children with only partial response (PR 12%) or nonresponse (NR 8%) to intensive induction therapy was quite high in all three trials. Whereas the PR rate did not differ significantly, the percentage of NR was higher than in other children with HR-AML (P ¼ 0.049). The frequency of early death (n ¼ 3) or death in CR (n ¼ 2) was low in children with AMKL.
The estimated 5-year event free (EFS), disease free (DFS) and overall survival (OS) of the total group was 3475, 4676, and 4276%, respectively. Causes of death were relapse (n ¼ 32), NR (n ¼ 6), SCT-related complications (n ¼ 6), or early death (n ¼ 3). Comparing the patients with AMKL to the total group of children with HR-AML (n ¼ 736) treated in the AML-BFM studies, we found a similar EFS (3475 vs 4072%; P log rank ¼ 0.22) and OS (4276 vs 5272%; P log rank ¼ 0.17). The outcome of children with AMKL in the AML-BFM studies was superior to that of the recently published study at the St Jude Children's Research Hospital (SJCRH), which reported a 2-year OS of only 14%. 3 However, the British Medical Research Council (MRC) trials did not identify the AMKL as an AMLsubtype with an especially poor outcome. 4, 5 Considering gender, age, blast count at day 15 of treatment or cytogenetic subgroups in our study, no significant differences could be found.
The cumulative incidence of relapse (overall 3778%) decreased from 4774% in study AML-BFM 87 to 3478% in studies AML-BFM 93 and 98. The time to relapse in AMKL (0.8 years; 0.3 to 5.6 years) was similar to other HR-AML (0.9 years, 0.2 to 6.7 years; P ¼ 0.8). However, only 10 out of 32 patients with relapse achieved a 2nd CR (31%), and only one of them survived in CR (follow-up 12.3 years). The 3-year OS after relapse was 775%, and therewith significantly lower than in other relapsed HR-AML patients (n ¼ 250; 3-year OS after relapse 2373%; P difference in 3 year o0.003). Seven children with AMKL were transplanted in 2nd CR, however, none of them survived.
The outcome was likewise poor in 10 of 19 children with PR (n ¼ 11) or NR (n ¼ 8) to induction treatment who were transplanted (alloSCT); only two of them stayed alive (followup 1 and 2 year(s), respectively). Four children died from complications of SCT, the others from relapse. Out of the remaining nine PR/NR children, eight died from disease (n ¼ 6) or infection (n ¼ 2). One child with PR to first-line treatment achieved CR with further intensive therapy and survived (follow-up 11 years). In line with these results, Athale et al 3 described a poor prognosis in these patients, independent of the applied treatment. In addition, Dastugue et al 6 reported the phenomenon that second-line treatment failed in almost all children. Duchayne et al 7 found long-lasting DFS in children with t(1;22)-positive AMKL if CR was achieved, but a poor outcome in children who failed to attain remission.
Regarding children who have been transplanted in 1st CR, the conditioning regimens for SCT were TBI and cyclophophamide (n ¼ 1) or busulfan/cyclophosamide (n ¼ 12). The 5-year DFS and OS were 28713 and 43715%, respectively, which did not differ from children achieving remission and being treated with CHT only (n ¼ 54; DFS 5077% P mantel-Byar ¼ 0.11, OS 5477% P mantel-Byar ¼ 0.37). This outcome was within the same range as reported from the single centre trial at SJCRH with a 2-year OS of 40%. 3 The results of a recently published report on AMKL from the European Group for Blood and Marrow Transplantation (EBMT) in which the authors recommended alloSCT were hardly comparable because children with and without Down's Syndrome were analysed together, and a control group was lacking. 8 The results of the AML-BFM trials with chemotherapy only were supported by the data of the British MRC 10 and 12 trials, which reported an outcome similar to that of the intermediate risk group (EFS 47%). 4 Summarized, there is no proven benefit of alloSCT in 1st CR. In addition, in children who failed to achieve CR or relapsed, SCT could not improve outcome. The most relevant prognostic factor seems to be the initial treatment response.
Whereas outcome was extremely poor in the early AML-BFM 87 trial (EFS 1177%, OS 2179%); a significant improvement was achieved in the following trials AML-BFM 93 and 98 (EFS 4176% P log rank o0.008; OS 4976% P log rank ¼ 0.013 (Figure 1) ). The results of other children with HR-AML did not show such a strong improvement of EFS (AML-BFM 87 n ¼ 191, EFS 3373%, AML-BFM 93/98 n ¼ 545, EFS 4272%, P log rank ¼ 0.02. The CR and OS rates in the AML-BFM 87 study were comparable to the results reported by Athale et al 3 from the SJCRH (CR 50%, OS 14%). The main difference between the AML-BFM 87 or SJCRH and the AML-BFM 93/98 treatment regimens was the increased cumulative dosage of cytarabine (48-fold) and anthracyclines (1.2-to 1.6-fold) during induction (calculated within the first 7 weeks of therapy). The additional administration of 2-CDA in the SJCRH protocols seemed to be ineffective in AMKL. 9 The association between dose intensity and outcome was also supported by the British MRC trials that administered an intensive treatment regimen, which was comparable to that of the AML-BFM 93/98 trials. 4, 5 In summary, AMKL remains an AML subgroup with a poor outcome in spite of all available treatment options. Intensification of induction treatment as scheduled in the AML-BFM studies resulted in an improved prognosis compared to historical control. AlloSCT revealed no additional benefit. Further research is necessary to develop new and better treatment options to improve prognosis in these children.
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